<DOC>
	<DOCNO>NCT02668692</DOCNO>
	<brief_summary>To compare efficacy safety LEO 80185 gel Dovobet® ointment treatment psoriasis Japanese subject .</brief_summary>
	<brief_title>LEO 80185 Gel ( Calcipotriol Hydrate Plus Betamethasone Dipropionate ) Japanese Subjects With Psoriasis</brief_title>
	<detailed_description>A phase 3 , national , multi-centre , 4-week , prospective , randomise , control , parallel-group , open trial LEO 80185 gel versus Dovobet® ointment Japanese subject psoriasis vulgaris .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>1 . Informed consent obtain . 2 . Japanese subject 3 . Aged 20 year 4 . Clinical diagnosis psoriasis vulgaris amenable topical treatment less equal 30 % BSA 5 . A target psoriasis lesion scalp nonscalp area body , lesion minimum size 10 cm2 score least 2 ( mild ) clinical sign ( redness , thickness scaliness ) . 6 . Females childbearing potential must negative result urine pregnancy test Day 1 ( Visit 1 ) must agree use adequate method birth control . 7 . Able communicate ( sub ) investigator understand comply requirement trial . 1 . Systemic use biological treatment potential effect psoriasis vulgaris 2 . Systemic treatment therapy biological treatment potential effect psoriasis vulgaris 3 . PUVA therapy , UVB therapy UVA therapy 4 . Topical treatment psoriasis area treat trial medication 5 . Topical treatment psoriasis face , genitals skin fold vitamin D analogue , potent potent corticosteroid immunosuppressant 6 . Topical treatment condition psoriasis vitamin D analogue , potent potent corticosteroid immunosuppressant 7 . Planned initiation , change , concomitant medication may affect psoriasis vulgaris 8 . Patients follow disorder ( ) symptom ( b ) present area treat trial medication : ( ) viral ( e.g. , herpes varicella ) lesion skin , fungal , spirochetal bacterial skin infection , parasitic infection , skin manifestation relation syphilis tuberculosis , rosacea , acne vulgaris , atrophic skin , stria atrophicae , ichthyosis , acne rosacea , ulcer , burn , frostbite , wound , animal skin disease ( scabies , crab , louse , etc . ) ( b ) fragility skin vein . 9 . Other inflammatory skin disease may confound evaluation psoriasis vulgaris . 10 . Erythrodermic , exfoliative pustular psoriasis 11 . Planned excessive exposure area treat trial medication either natural artificial sunlight 12 . Known suspected disorder calcium metabolism associate hypercalcaemia , albumincorrected serum calcium reference range 13 . Known suspect severe renal insufficiency , severe hepatic disorder severe heart disease . 14 . Known suspected hypersensitivity component investigational product . 15 . Clinical sign symptoms Cushing 's disease Addison 's disease 16 . Treatment nonmarketed drug substance 17 . Current participation interventional clinical trial 18 . Previously randomise trial 19 . Females pregnant , wish become pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>LEO 80185 gel , calcipotriol , betamethasone</keyword>
</DOC>